Wilkinson Walsh Celebrates Another Outstanding Year of High Stakes Trials and Accolades for the Next Generation of Trial Lawyers

WASHINGTON –Wilkinson Walsh enters its fifth year having cemented its status as the premier trial litigation boutique in the country. 2019 featured three high-stakes, high-pressure trials, in which different partners served as lead trial counsel and eight partners in total had stand-up roles. The firm continued to receive accolades for its successes in delivering results to its clients while deepening its diverse bench of go-to litigators.

Alexandra Walsh Named Law 360 Trials MVP of the Year

WASHINGTON – Wilkinson Walsh Founding Partner Alexandra Walsh was named one of Law360’s 2019 Trial MVPs of the Year. The award recognizes Walsh for leading “trial teams to a string of crucial victories for Bayer AG this year, persuading juries to reject a certified class action attacking the company’s One A Day vitamins as well as suits over its blood thinner Xarelto.”

American Healthcare Leader: “Wilkinson Walsh Help Bayer Stand Its Ground”

WASHINGTON — After the Wilkinson Walsh team won a decisive trial victory for Bayer in a $600 million certified consumer class action lawsuit brought on behalf of One A Day multivitamin consumers, American Healthcare Leader’s (AHL) Sara Deeter highlighted how Walsh and Eskovitz’s “confidence and strategy” helped Bayer win a “resounding victory” in such a “high stakes” case. Without calling any witnesses in the defense case, the Wilkinson Walsh team — led by Sean Eskovitz, Alex Walsh, James Rosenthal, and Kieran Gostin — relied on devastating cross-examinations of plaintiffs’ expert and fact witnesses, which were “pivotal” and “yielded further important insights.” The cross-examinations were so effective that it only took the jury one hour to reject plaintiffs’ claims that Bayer had misrepresented the health benefits of One A Day multivitamins.  The feature acknowledged one of Wilkinson Walsh’s key strategies to engaging with the jury in a case that centered on …

Wilkinson Walsh’s Beth Wilkinson, Alex Walsh Again Named “Top Women in Litigation” by Benchmark

WASHINGTON – For the second consecutive year, Wilkinson Walsh founding partners Beth Wilkinson and Alexandra Walsh were ranked among Benchmark Litigation’s “Top 250 Women in Litigation,” a recognition of “the most distinguished women in the world of litigation.” In addition, Beth Wilkinson was again named among the “Top 10 Female Litigators” in the country, which recognizes “a separate but elite group of leading lawyers who have been nominated specifically for their litigious acumen.” “Beth and Alex’s repeated recognition by Benchmark is a testament to their leadership at our firm and their expertise in the courtroom,” said Wilkinson Walsh Managing Partner Brant Bishop. “In an industry that continues to suffer from an underrepresentation of women – especially in leadership roles – we are proud to have trailblazers like Beth and Alex.” Benchmark’s extensive research process encompasses months of investigation into the individual litigators’ professional activities as well as client feedback surveys and individual …

Wilkinson Walsh Again Named “Boutique Firm of the Year” by Benchmark

WASHINGTON, D.C. — Benchmark Litigation again named Wilkinson Walsh the “Boutique Firm of the Year” during its annual awards ceremony in New York City — the second time in three years that Wilkinson Walsh has received the recognition. This prestigious award recognizes Wilkinson Walsh’s high-profile trial wins over the last year, including a defense verdict for the National Collegiate Athletic Association (NCAA) in McNair v. NCAA and multiple state-court bellwether trial victories for Bayer in trials involving the blood-thinner Xarelto. Wilkinson Walsh also achieved several other pre- and post-trial victories in 2018, including judgment granted as a matter of law to Wilkinson Walsh’s clients Oculus and Facebook on plaintiffs’ false designation claim in Zenimax Media et al. v. Oculus VR and complete dismissal, before any discovery, of a securities fraud class action case in In re MAXIMUS, Inc. Securities Litig. “We are deeply appreciative of Benchmark’s recognition of our firm for …

Litigation Daily: “Killer Crosses: How Wilkinson Walsh Partners Shredded Witnesses in $600M Save for Bayer”

After the Wilkinson Walsh team, led by Sean Eskovitz, Alex Walsh, James Rosenthal, and Kieran Gostin, won a decisive victory for Bayer in a $600 million certified consumer class action lawsuit brought on behalf of One A Day multivitamin consumers, Litigation Daily‘s Jenna Greene wrote about how Eskovitz and Walsh were “so good” at the cross-examinations that “the Wilkinson Walsh team called no defense witnesses. They annihilated the case on crosses alone”: If cross-examination is an art form, then Wilkinson Walsh name partners Alexandra Walsh and Sean Eskovitz (pictured above) are masters. The duo led a trial team defending Bayer AG, which faced a $600 million certified consumer class action over its One A Day multivitamin. The plaintiffs alleged Bayer made false and misleading claims that One A Day supported heart health, immunity and physical energy. How good were the cross-examinations? So good that that the Wilkinson Walsh team called no defense witnesses. They annihilated the case on …

Wilkinson Walsh Secures Trial Win for Bayer in $600 Million One A Day Class Action

WASHINGTON, D.C. — The Wilkinson Walsh team, led by Sean Eskovitz, Alex Walsh, James Rosenthal, and Kieran Gostin, won a decisive victory for Bayer in a $600 million certified consumer class action lawsuit brought on behalf of One A Day multivitamin consumers.  Without calling any witnesses in the defense case, the team relied on devastating cross-examinations of plaintiffs’ expert and fact witnesses to convince the jury to reject plaintiffs’ claims that Bayer had misrepresented the health benefits of One A Day multivitamins.  The jury deliberated for just an hour before returning a complete defense verdict.  The class action suit, filed on behalf of purchasers of One A Day multivitamins in California, New York, and Florida, challenged as false and misleading Bayer’s claims that One A Day multivitamins support heart health, immunity, and physical energy. Plaintiffs originally sought over $4 billion in damages, which Wilkinson Walsh successfully reduced to $600 million …

Wilkinson Walsh Celebrates Banner Year of High Stakes Trial Wins By Next Generation Of Trial Lawyers

WASHINGTON – Wilkinson Walsh is racing into its fourth year after notching a series of high-profile victories, led by a large and diverse group of partners. In 2018, all of Wilkinson Walsh’s partners participated in trials and case-dispositive hearings, and several other attorneys achieved significant on-their-feet experience, including through pro bono cases. The firm earned repeated recognition for the depth and successes of its bench and added a new crop of talented litigators to its roster. Wilkinson Walsh won three trials in 2018, each of which was first-chaired by a different partner: On April 27, 2018, Wilkinson Walsh, led by Brian Stekloff, Jeremy Barber, and Lori McGill, won a unanimous defense verdict for Bayer and Johnson & Johnson subsidiary Janssen Pharmaceuticals in Russell v. Janssen Pharmaceuticals, Inc., the second state-court Xarelto bellwether trial in the Pennsylvania Court of Common Pleas. On May 21, 2018, Wilkinson Walsh, led by Kosta Stojilkovic …

Appeals Court Upholds Major Antitrust Win for Wilkinson Walsh Client Georgia Pacific

WASHINGTON,D.C. — The U.S. Court of Appeals for the Seventh Circuit unanimously upheld a major trial court win for Wilkinson Walsh client Georgia Pacific, affirming the dismissal of a high stakes antitrust class action lawsuit involving over $10 billion in claimed damages. Georgia Pacific hired Wilkinson Walsh to handle all aspects of summary judgment briefing and trial after the trial court certified Plaintiffs’ proposed class. The Wilkinson Walsh team, led by Beth Wilkinson, Alexandra Walsh, Brant Bishop, and Rakesh Kilaru, developed an evidentiary record focused on the absence of any evidence against Georgia Pacific, and filed independent briefs challenging Plaintiffs’ expert witnesses and seeking summary judgment. In June 2017, the court issued a Daubert opinion that imposed key limits on the testimony Plaintiffs’ witnesses could offer at trial, adopting several of Wilkinson Walsh’s arguments. On August 3, 2017, Wilkinson Walsh won summary judgment for Georgia Pacific. The court’s decision came …

Benchmark Names Beth Wilkinson an “Elite” Top 100 Trial Lawyer

Washington, D.C. — Wilkinson Walsh Founding Partner Beth Wilkinson has been named a Top 100 Trial Lawyer by Benchmark Litigation 2018. The award recognizes “elite trial strategists” for their successes in the courtroom. “At this point, it goes without saying that Beth’s recognitions are well-deserved. She is continuously recognized as a top trial lawyer precisely because of the high-profile victories she delivers for her clients and her role as a trailblazer in and outside of the courtroom,” said Wilkinson Walsh Founding Partner Alexandra Walsh. “She is a role model for our firm’s younger associates, a force to be reckoned with when in front of a jury, and a paragon of success in the legal community at large.” Since founding Wilkinson Walsh less than three years ago, Beth has notched a string of standout trial victories, been honored and recognized for her and Wilkinson Walsh’s various successes, and built the firm …